MELVILLE, N.Y., May 6 /PRNewswire/ -- Today, Fougera, a division of Nycomed US Inc., announced it has received FDA approval to bring to market the first generic Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution). The generic formulation compares to Dovonex(R) by Warner-Chilcott.
Fougera's Calcipotriene Topical Solution is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp (see product package insert for full prescribing information). It is available in a 60 mL bottle (NDC # 0168-0400-60).
"Fougera has received more FDA approvals for topical products during the past seven years than any other generic company. Today's announcement that we are first-to-market with Calcipotriene Topical Solution is another example of our ongoing commitment to provide safe, effective and affordable options to health care providers and their patients," stated David Klaum, Senior Vice President, Commercial Business Operations.
Founded in 1849, Fougera is the largest of the three Nycomed US Inc. divisions and is the leading manufacturer and distributor of a wide range of topical steroids, antibiotics and antifungal products. For more information on Fougera's complete line of products, please call Fougera Customer Service at (800) 645-9833 or visit the company online at http://www.fougera.com.
About Nycomed US
Nycomed US, Inc. (formerly ALTANA Inc) is a subsidiary of Nycomed, and also operates two additional divisions in the US focused on specialty pharmaceuticals in dermatology. The PharmaDerm(R) division of Nycomed is dedicated to bringing innovative products to the dermatologists so they can best care for their patients. Nycomed US, Inc. and its PharmaDerm Division recently announced the acquisition of Bradley Pharmaceuticals, a global specialty company with 3 divisions-Doak Dermatologics, Kenwood Therapeutics, and A. Aarons. The Bradley product line will be combined with the current offerings of PharmaDerm, enabling the Company to offer more therapeutic choices and enhanced customer service. Combined with Nycomed's Fougera Division, Nycomed becomes a leader in the dermatology market. Nycomed US also markets and sells Savage Laboratories products, which focus on emergency care.
Copyright©2008 PR Newswire.
All rights reserved